[Skip to Content]

Upstate Active Clinical Trials

Study Title:

AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma

What is the purpose of the study? (in Layman's terms, please describe the study)

Determine the feasibility of adding cabozantinib to standard MAP (high dose methotrexate, doxorubicin, and cisplatin) chemotherapy in patients with newly diagnosed metastatic osteosarcoma with a resectable primary tumor. Determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival than MAP chemotherapy alone in patients with localized, resectable osteosarcoma. Determine whether MAP chemotherapy plus cabozantinib results in more favorable event-free survival than MAP chemotherapy alone in patients with metastatic, pelvic and unresectable osteosarcoma.

Upstate Institutional Review Board (IRB) Number:

2024216

Study/Protocol ID:

AOST2032

Study Phase:

III

Patient Age Group:

Adults and Children

Principal Investigator:

Melanie A Comito

What is involved if I participate?

  • How long is the study?
    Receive treatment for 16 months, but will be followed on study for 10 years.
  • Is transportation provided or reimbursed?
    No
  • Is parking provided or reimbursed?
    Yes
  • What tests and procedures are involved?
    Blood draws, imaging, surgery, and radiation.

Where will the study take place?

Upstate Cancer Center & SUNY Upstate Medical University

Other Information:

N/A

ClinicalTrials.Gov ID:

NCT05691478

For more information about this trial go to ClinicalTrials.Gov

Who can I contact for more information?

Name: Suzanne M Majewski
Phone: 315-464-7232
Email: [email protected]

Return to Previous Page || Search Again

Top